A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)

Trial Profile

A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Jul 2018

At a glance

  • Drugs Duvelisib (Primary)
  • Indications Peripheral T-cell lymphoma
  • Focus Therapeutic Use
  • Acronyms PRIMO
  • Sponsors Verastem Oncology
  • Most Recent Events

    • 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 16 May 2018 According to a Verastem media release, data from this study will be presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO)
    • 03 May 2018 According to a Verastem media release, Dr. Horwitz is an investigator on this PRIMO study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top